40 -20 -10 6 35% 34 23 (12) INTERNATIONAL APPLICATION PUBLISHED (19) World Intellectual Property Organization International Bureau UNDER THE PATENT COOPERATION TREATY (PCT) IiiiionolivivivillEviiliololoillEvivivEmionvitiovois (10) International Publication Number WO 2019/014586 Al PCT (43) International Publication Date 17 January 2019 (17.01.2019) W I PO I Point Boulevard, Suite 400, South San Francisco, California 94080 (US). (74) Agent: SHORE, David E. et al.; Choate, Hall & Ste- wart LLP, Two International Place, Boston, Massachusetts 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/US2018/042074 (22) International Filing Date: 13 July 2018 (13.07.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/532,889 14 July 2017 (14.07.2017) US (71) Applicant: CYTOMX THERAPEUTICS, INC. [US/US]; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). (72) Inventors: DESNOYERS, Luc Roland; c/o CytomX Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). DUPAGE, Amy Grace; c/o CytomX Therapeutics, Inc., 151 Oyster (54) Title: ANTI-CD166 ANTIBODIES AND USES THEREOF Figure 13 Prevalence of CD166 Expression Across Metastatic Indications Number of cases scored -80+ cases Secondary Site 4 7 100-- — 178 % Strong /Mo dera te Exp ression 62 75 50 21 50 25 45 I I 51 71 25 0 e' S b 4 S cc` cc' 4' 9 + ..te s e\ t * 'b- A e t> e • 0 z 42<\' ci e ci° b 3 o <(% ,s 4 b *b c> „, t y , o t z e e e gf;. \ CP se e ( a. ckss s c> ez, kg ke as (20. €.> \ \ .tc` i e b 4, 0 'b. *A e e e e te b t e 43 43 ‘ 9 „ . 4 4 \ f t , c). cc• c° N t b- 2 b , e - - xe 16 t . 4 ‘ 3 Na .0 1-1 GC 71. 1-1 O 1-1 O (57) : The present invention provides, among other things, an antibody or antigen-binding polypeptide that binds or is capa- ble of binding CD 166, compositions including the same, and uses thereof. In certain embodiments, an anti-CD 166 antibody or anti- gen-binding polypeptide of the present invention binds or is capable of binding all or a portion of an intracellular domain (\'ICD\') of CD 166. The present invention also includes, among other things, a nucleic acid molecule encoding an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166. In various embodiments, an anti-CD 166 antibody or antigen-binding polypep- tide is useful in a method of detecting or treating a condition or disease. [Continued on next page] WO 2019/014586 Al IIIIIIIIIIIIHNEHICIII111111111111111111111111111111111111111111111111111111 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
ANTI-CD166 ANTIBODIES AND USES THEREOF